• AngioDynamics reported an EPS of -$0.15, missing estimates but exceeded revenue expectations with $79.43 million.
• The company experienced double-digit growth in its medical technology segment, contributing to increased profitability despite a negative P/E ratio of approximately -14.67.
• AngioDynamics raised its fiscal year 2026 adjusted earnings per share guidance, with analysts showing positive sentiment towards the company's future performance.

AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company that focuses on innovative solutions to improve blood flow, expand cancer treatment options, and enhance patient quality of life. The company recently reported its Q2 2026 earnings, revealing an earnings per share (EPS) of -$0.15, which was below the estimated -$0.10. However, the company exceeded revenue expectations, generating $79.43 million compared to the estimated $76.7 million.

The earnings call, as highlighted by Seeking Alpha, provided insights into AngioDynamics' financial performance and strategic direction. Despite the negative EPS, the company experienced double-digit growth in its medical technology segment, contributing to increased profitability. This growth is crucial for the company as it navigates financial challenges, including a negative price-to-earnings (P/E) ratio of approximately -14.67.

Analysts had forecasted a quarterly loss of 10 cents per share, deeper than the 4 cents per share loss from the same quarter last year. Despite the larger-than-expected loss, AngioDynamics' revenue of $79.43 million surpassed the previous year's $72.84 million, indicating a positive trend in sales. The company's price-to-sales ratio of about 1.56 suggests that investors are paying $1.56 for every dollar of sales, reflecting confidence in its revenue-generating capabilities.

On October 2, AngioDynamics raised its fiscal year 2026 adjusted earnings per share guidance, signaling a positive outlook for future performance. However, the company's shares declined by 1.8%, closing at $12.87. Despite this, Canaccord Genuity analyst William Plovanic maintained a Buy rating and increased the price target from $17 to $18, indicating positive sentiment from analysts regarding the company's potential.

AngioDynamics' financial metrics reveal challenges, such as a negative enterprise value to operating cash flow ratio of around -55.21, indicating difficulties in generating positive cash flow from operations. However, the company maintains a strong current ratio of about 2.29, suggesting it has a solid ability to cover short-term liabilities with its short-term assets. This financial stability is crucial as the company continues to focus on growth and innovation in the medical technology sector.